Humanis, a subsidiary of Saya Holding and one of Turkey’s top 500 industrial enterprises, is setting its sights on the U.S. market after becoming the first Turkish pharmaceutical company to export to China. Targeting $250 million in revenue and a production volume of 120 million units for 2025, the company has initiated a five-year strategic roadmap to enter the American market under FDA standards.
Powering 1 in 20 Medicines in Turkey
Since starting production in 2013, Humanis has rapidly scaled to account for 1 out of every 20 boxes of medicine produced in Turkey. With a robust export network spanning Europe, the Middle East, Central Asia, and Africa, the company holds prestigious EU GMP and Canada GMP certifications. Its European operations are further strengthened by Humanis GmbH, established in Germany to ensure a direct and sustainable presence in the EU.
The China Milestone: A Springboard for the U.S.
Having cleared the high regulatory hurdles of the Chinese market, Humanis is now re-engineering its R&D and operational infrastructure for the United States. By aligning its quality, traceability, and validation processes with FDA (U.S. Food and Drug Administration) requirements, the company views this move not just as an export expansion, but as a total transformation of its global manufacturing standards.
Top 5 R&D Hub in Europe
At the heart of this growth lies the 2,500-square-meter R&D Center in Çerkezköy, which ranks among the top five largest facilities of its kind in Turkey and Europe. Leveraging this technical prowess, Humanis:
Manages over 200 licensed products across 12 therapeutic areas.
Is preparing to enter the oncology and diabetes sectors within the next three years.
Contributes 400 million TRY annually to public finances through innovative treatments for rare diseases (such as CTX).
Sustainable Growth Through Green Energy
Beyond production metrics, Humanis is setting industry benchmarks for sustainability. Following an $8 million investment in Solar Power Plants (GES), the company now meets 70% of its energy needs through solar power. Additionally, it has achieved a remarkable 74% recycling rate across its operations.
At Saya Holding, we have established a resilient structure by integrating pharmaceuticals, real estate, and defense technologies within the same strategic framework. We are not just managing today; we are preparing for tomorrow’s risks through sustainable growth." > — Cem Mengi, Chairman of the Board, Saya Holding
